安全可靠的人工智能在糖尿病管理中的方法论。

IF 4.1 Q2 ENDOCRINOLOGY & METABOLISM
Remco Jan Geukes Foppen, Vincenzo Gioia, Shreya Gupta, Curtis L Johnson, John Giantsidis, Maria Papademetris
{"title":"安全可靠的人工智能在糖尿病管理中的方法论。","authors":"Remco Jan Geukes Foppen, Vincenzo Gioia, Shreya Gupta, Curtis L Johnson, John Giantsidis, Maria Papademetris","doi":"10.1177/19322968241304434","DOIUrl":null,"url":null,"abstract":"<p><p>The use of artificial intelligence (AI) in diabetes management is emerging as a promising solution to improve the monitoring and personalization of therapies. However, the integration of such technologies in the clinical setting poses significant challenges related to safety, security, and compliance with sensitive patient data, as well as the potential direct consequences on patient health. This article provides guidance for developers and researchers on identifying and addressing these safety, security, and compliance challenges in AI systems for diabetes management. We emphasize the role of explainable AI (xAI) systems as the foundational strategy for ensuring security and compliance, fostering user trust, and informed clinical decision-making which is paramount in diabetes care solutions. The article examines both the technical and regulatory dimensions essential for developing explainable applications in this field. Technically, we demonstrate how understanding the lifecycle phases of AI systems aids in constructing xAI frameworks while addressing security concerns and implementing risk mitigation strategies at each stage. In addition, from a regulatory perspective, we analyze key Governance, Risk, and Compliance (GRC) standards established by entities, such as the Food and Drug Administration (FDA), providing specific guidelines to ensure safety, efficacy, and ethical integrity in AI-enabled diabetes care applications. By addressing these interconnected aspects, this article aims to deliver actionable insights and methodologies for developing trustworthy AI-enabled diabetes care solutions while ensuring safety, efficacy, and compliance with ethical standards to enhance patient engagement and improve clinical outcomes.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241304434"},"PeriodicalIF":4.1000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672366/pdf/","citationCount":"0","resultStr":"{\"title\":\"Methodology for Safe and Secure AI in Diabetes Management.\",\"authors\":\"Remco Jan Geukes Foppen, Vincenzo Gioia, Shreya Gupta, Curtis L Johnson, John Giantsidis, Maria Papademetris\",\"doi\":\"10.1177/19322968241304434\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The use of artificial intelligence (AI) in diabetes management is emerging as a promising solution to improve the monitoring and personalization of therapies. However, the integration of such technologies in the clinical setting poses significant challenges related to safety, security, and compliance with sensitive patient data, as well as the potential direct consequences on patient health. This article provides guidance for developers and researchers on identifying and addressing these safety, security, and compliance challenges in AI systems for diabetes management. We emphasize the role of explainable AI (xAI) systems as the foundational strategy for ensuring security and compliance, fostering user trust, and informed clinical decision-making which is paramount in diabetes care solutions. The article examines both the technical and regulatory dimensions essential for developing explainable applications in this field. Technically, we demonstrate how understanding the lifecycle phases of AI systems aids in constructing xAI frameworks while addressing security concerns and implementing risk mitigation strategies at each stage. In addition, from a regulatory perspective, we analyze key Governance, Risk, and Compliance (GRC) standards established by entities, such as the Food and Drug Administration (FDA), providing specific guidelines to ensure safety, efficacy, and ethical integrity in AI-enabled diabetes care applications. By addressing these interconnected aspects, this article aims to deliver actionable insights and methodologies for developing trustworthy AI-enabled diabetes care solutions while ensuring safety, efficacy, and compliance with ethical standards to enhance patient engagement and improve clinical outcomes.</p>\",\"PeriodicalId\":15475,\"journal\":{\"name\":\"Journal of Diabetes Science and Technology\",\"volume\":\" \",\"pages\":\"19322968241304434\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-12-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672366/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Diabetes Science and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/19322968241304434\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19322968241304434","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

人工智能(AI)在糖尿病管理中的应用正在成为一种有前途的解决方案,可以改善治疗的监测和个性化。然而,这些技术在临床环境中的整合带来了与安全、保障和患者敏感数据合规性相关的重大挑战,以及对患者健康的潜在直接后果。本文为开发人员和研究人员提供了在糖尿病管理人工智能系统中识别和解决这些安全性、安全性和合规性挑战的指导。我们强调可解释的人工智能(xAI)系统作为确保安全性和合规性、培养用户信任和知情临床决策的基础策略,这在糖尿病护理解决方案中至关重要。本文考察了在该领域开发可解释应用程序所必需的技术和监管方面。从技术上讲,我们展示了理解人工智能系统的生命周期阶段如何有助于构建xAI框架,同时在每个阶段解决安全问题并实施风险缓解策略。此外,从监管的角度来看,我们分析了食品和药物管理局(FDA)等实体建立的关键治理、风险和合规性(GRC)标准,提供了具体的指导方针,以确保人工智能糖尿病治疗应用的安全性、有效性和道德完整性。通过解决这些相互关联的方面,本文旨在提供可操作的见解和方法,以开发值得信赖的人工智能糖尿病护理解决方案,同时确保安全性、有效性和符合道德标准,以提高患者参与度和改善临床结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Methodology for Safe and Secure AI in Diabetes Management.

The use of artificial intelligence (AI) in diabetes management is emerging as a promising solution to improve the monitoring and personalization of therapies. However, the integration of such technologies in the clinical setting poses significant challenges related to safety, security, and compliance with sensitive patient data, as well as the potential direct consequences on patient health. This article provides guidance for developers and researchers on identifying and addressing these safety, security, and compliance challenges in AI systems for diabetes management. We emphasize the role of explainable AI (xAI) systems as the foundational strategy for ensuring security and compliance, fostering user trust, and informed clinical decision-making which is paramount in diabetes care solutions. The article examines both the technical and regulatory dimensions essential for developing explainable applications in this field. Technically, we demonstrate how understanding the lifecycle phases of AI systems aids in constructing xAI frameworks while addressing security concerns and implementing risk mitigation strategies at each stage. In addition, from a regulatory perspective, we analyze key Governance, Risk, and Compliance (GRC) standards established by entities, such as the Food and Drug Administration (FDA), providing specific guidelines to ensure safety, efficacy, and ethical integrity in AI-enabled diabetes care applications. By addressing these interconnected aspects, this article aims to deliver actionable insights and methodologies for developing trustworthy AI-enabled diabetes care solutions while ensuring safety, efficacy, and compliance with ethical standards to enhance patient engagement and improve clinical outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Diabetes Science and Technology
Journal of Diabetes Science and Technology Medicine-Internal Medicine
CiteScore
7.50
自引率
12.00%
发文量
148
期刊介绍: The Journal of Diabetes Science and Technology (JDST) is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society. JDST covers scientific and clinical aspects of diabetes technology including glucose monitoring, insulin and metabolic peptide delivery, the artificial pancreas, digital health, precision medicine, social media, cybersecurity, software for modeling, physiologic monitoring, technology for managing obesity, and diagnostic tests of glycation. The journal also covers the development and use of mobile applications and wireless communication, as well as bioengineered tools such as MEMS, new biomaterials, and nanotechnology to develop new sensors. Articles in JDST cover both basic research and clinical applications of technologies being developed to help people with diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信